US20060216267A1 - Hydrophobic elastomeric polymer chemistry device for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis - Google Patents

Hydrophobic elastomeric polymer chemistry device for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis Download PDF

Info

Publication number
US20060216267A1
US20060216267A1 US11284649 US28464905A US2006216267A1 US 20060216267 A1 US20060216267 A1 US 20060216267A1 US 11284649 US11284649 US 11284649 US 28464905 A US28464905 A US 28464905A US 2006216267 A1 US2006216267 A1 US 2006216267A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
diisocyanate
composition
diamine
carrier
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11284649
Inventor
Stephen Kovacs
Jerry Chesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roof Matrix Inc
Original Assignee
Roof Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015Drug-containing film-forming compositions, e.g. spray-on
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B27WORKING OR PRESERVING WOOD OR SIMILAR MATERIAL; NAILING OR STAPLING MACHINES IN GENERAL
    • B27KPROCESSES, APPARATUS OR SELECTION OF SUBSTANCES FOR IMPREGNATING, STAINING, DYEING, BLEACHING OF WOOD OR SIMILAR MATERIALS, OR TREATING OF WOOD OR SIMILAR MATERIALS WITH PERMEANT LIQUIDS, NOT OTHERWISE PROVIDED FOR; CHEMICAL OR PHYSICAL TREATMENT OF CORK, CANE, REED, STRAW OR SIMILAR MATERIALS
    • B27K3/00Impregnating wood, e.g. impregnation pretreatment, for example puncturing; Wood impregnation aids not directly involved in the impregnation process
    • B27K3/02Processes; Apparatus
    • B27K3/15Impregnating involving polymerisation including use of polymer-containing impregnating agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B27WORKING OR PRESERVING WOOD OR SIMILAR MATERIAL; NAILING OR STAPLING MACHINES IN GENERAL
    • B27KPROCESSES, APPARATUS OR SELECTION OF SUBSTANCES FOR IMPREGNATING, STAINING, DYEING, BLEACHING OF WOOD OR SIMILAR MATERIALS, OR TREATING OF WOOD OR SIMILAR MATERIALS WITH PERMEANT LIQUIDS, NOT OTHERWISE PROVIDED FOR; CHEMICAL OR PHYSICAL TREATMENT OF CORK, CANE, REED, STRAW OR SIMILAR MATERIALS
    • B27K3/00Impregnating wood, e.g. impregnation pretreatment, for example puncturing; Wood impregnation aids not directly involved in the impregnation process
    • B27K3/16Inorganic impregnating agents
    • B27K3/22Compounds of zinc or copper
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B27WORKING OR PRESERVING WOOD OR SIMILAR MATERIAL; NAILING OR STAPLING MACHINES IN GENERAL
    • B27KPROCESSES, APPARATUS OR SELECTION OF SUBSTANCES FOR IMPREGNATING, STAINING, DYEING, BLEACHING OF WOOD OR SIMILAR MATERIALS, OR TREATING OF WOOD OR SIMILAR MATERIALS WITH PERMEANT LIQUIDS, NOT OTHERWISE PROVIDED FOR; CHEMICAL OR PHYSICAL TREATMENT OF CORK, CANE, REED, STRAW OR SIMILAR MATERIALS
    • B27K3/00Impregnating wood, e.g. impregnation pretreatment, for example puncturing; Wood impregnation aids not directly involved in the impregnation process
    • B27K3/16Inorganic impregnating agents
    • B27K3/26Compounds of iron, aluminium, or chromium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B27WORKING OR PRESERVING WOOD OR SIMILAR MATERIAL; NAILING OR STAPLING MACHINES IN GENERAL
    • B27KPROCESSES, APPARATUS OR SELECTION OF SUBSTANCES FOR IMPREGNATING, STAINING, DYEING, BLEACHING OF WOOD OR SIMILAR MATERIALS, OR TREATING OF WOOD OR SIMILAR MATERIALS WITH PERMEANT LIQUIDS, NOT OTHERWISE PROVIDED FOR; CHEMICAL OR PHYSICAL TREATMENT OF CORK, CANE, REED, STRAW OR SIMILAR MATERIALS
    • B27K3/00Impregnating wood, e.g. impregnation pretreatment, for example puncturing; Wood impregnation aids not directly involved in the impregnation process
    • B27K3/16Inorganic impregnating agents
    • B27K3/28Compounds of arsenic or antimony

Abstract

A system and method for treating onychomycosis and skin conditions such as urushiol-induced allergic contact dermatitis comprises coating the affected nail or skin with a solution comprising an at least a primary diamine with modified diphenylmethane diisocyanates and a carrier solvent/reactant. A secondary diamine may be mixed with the primary diamine in an oligomeric, stoichiometrically balanced blend. Upon topical application, the carrier solvent/reactant evaporates, allowing polymerization of the remaining solution constituents to form a non-toxic, hydrophobic, elastomeric polyureathane linked copolymer coating that provides a barrier against moisture impregnation, inhibiting the growth of dermatophytes and urushiol-infected skin cells.

Description

    BACKGROUND
  • This application is a Continuation In Part of Ser. No. 10/757,294, which is a Continuation In Part of Ser. No. 10/223,991, both of which are incorporated herein by reference.
  • The present invention relates generally to a system and method of inhibiting the growth of onychomycosis (toe fungus) and skin conditions such as urushiol-induced allergic contact dermatitis (poison ivy, oak and sumac reactions), and in particular to a polymer chemistry device that provides a hydrophobic, elastomeric topical agent for inhibiting the growth of these conditions and for mitigating of the deleterious effects thereof.
  • Onychomycosis is a fungal infection of the nails commonly known as toe fungus, although it also attacks fingernails. Onychomycosis is caused primarily by dermatophytes, a type of fungi, such as Trichophyton rubrum and Trichophyton mentagrophytes. Yeasts such as Candida albicans cause a small number of cases, usually fingernail infections, and molds such as Scopulariopsis, Scytalidium, Acremonium, and Fusarium cause additional cases. Dermatophytes grow in the nail bed beneath the nail, and live off keratin, the protein in the nail. The condition usually begins towards the far end of the nail and may start with patches of white or yellow discoloration.
  • If the condition is left untreated, it will proceed to the base of the nail. It will attack the nail root (matrix) and cause the nail to grow very thick and deformed. The big toe is usually the first nail to be affected with the condition spreading to adjacent nails. In rare cases this condition can also affect the skin surrounding the nails. Debris may collect under the nail, causing a foul smell. The nail may thicken and become flaky. Thick toenails, in particular, may cause discomfort in shoes and may even make standing and walking painful for the affected individual. Onychomycosis of the fingernails may restrict typing, writing, and computer work; dressing; manual dexterity, fine touch, and sensitivity; and social interaction.
  • There are four types of onychomycosis. Distal and/or lateral subungual onychomycosis affects the nail bed and nail plate. Proximal subungual onychomycosis affects the proximal nail fold, with infection extending distally under the nail plate. Superficial white onychomycosis affects the top of the nail plate. Candidal onychomycosis affects the nail, skin, and mucous membranes.
  • Onychomycosis is often treated with terbinafine, an oral or topical antifungal agent (brand name: Lamisil®). Terbinafine is attracted to keratin, the food source of dermatophytes. Terbinafine acts by interfering with the ability of fungi to make sterols, which are an important part of the membrane that surrounds fungal cells and holds them together. Depriving the fungi of sterols weakens the cell membrane. Terbinafine is prescription medication. Topical terbinafine was approved by the FDA in 1993, and terbinafine oral tablets were approved in 1996. Other antifungal agents used the treatment of onychomycosis are griseofulvin (Fulvicine®; Gris-Peg®) and itraconazole (Sporanox®).
  • While medications for treating onychomycosis are readily available, they are prescription drugs that must be dispensed by a licensed medical professional. This usually requires that an individual suffering from onychomycosis be examined by a doctor, an expense many people cannot afford. Additionally, the prescription drugs themselves are expensive, and must be taken according to a dosing regimen, often for several months.
  • Poison ivy, oak, and sumac belong to a family of plants that produce urushiol, an oil that causes one of the most common allergic reactions in the United States. Experts estimate that up to 70% of the U.S. population is allergic to urushiol. The American Academy of Dermatology estimates that there are up to 50 million cases of urushiol-induced dermatitis annually in the United States alone. It accounts for 10% of all lost-time injuries in the United States Forest Service.
  • The allergen urushiol attaches to the skin within five minutes to two hours after exposure, most commonly by physical contact with the leaves or sap of plants such as poison ivy (Toxicodendron radicans or Rhus toxicodendron), poison oak (Toxicodendron diversilobum or Rhus diversiloba), or poison sumac (Toxicodendron vernix or Rhus vernix). Chemically, urushiol is harmless to humans. However, it binds to skin cell membranes and initiates a T-cell mediated immune response. That is, urushiol changes the configuration of skin cell membranes, so that the body's immune system no longer recognizes these cells as belonging to the body and attacks them as foreign. The result is an allergic eczematous contact dermatitis characterized by redness, swelling, papules, vesicles, bullac, and streaking. The dermatitis causes itching, and excessive scratching may lead to infection.
  • Zanfel® and Tecnu® are commercial preparations that remove urushiol from the skin, if applied immediately following exposure. However, they are less effective once an outbreak has occurred. Calamine lotion, antihistamines, and hydrocortisone ointment are over-the-counter treatments commonly used to abate the symptoms of urushiol-induced allergic contact dermatitis once an outbreak develops. A dermatologist may prescribe a course of corticosteroids to neutralize the itch. Commonly prescribed drugs are prednisone and betamethasone dipropionate (Diprolene®). These drugs require the inconvenience and expense of an examination and prescription by a dermatologist. A variety of home remedies are known (or alleged); most are ineffective.
  • A need exists in the art for an inexpensive, non-prescription, safe, easily applied device that inhibits the growth of onychomycosis and urushiol-induced allergic contact dermatitis, and that alleviates or at least mitigates the deleterious effects of these conditions.
  • SUMMARY OF THE INVENTION
  • As described in one or more parent applications, the present inventors developed various non-toxic, non-carcinogenic, hydrophobic, elastomeric, polymer-based chemistry formulations for wood preservation, as an alternative to the common practice of treating wood using heavy metals and environmentally hazardous ingredients. The inventors have made the surprising discovery that these chemistry formulations have efficacy as topical treatments for conditions such as onychomycosis and urushiol-induced allergic contact dermatitis.
  • In one embodiment of the present invention there is provided a method for treating onychomycosis or urushiol-induced allergic contact dermatitis by making a polymerizable, elastomeric, hydrophobic thermoset material, by combining at least a primary diamine with modified diphenylmethane diisocyanates and one or more carrier solvent/reactant(s) to form a solution; topically applying the solution to toe nail or fingernail infected with onychomycosis or skin experiencing an outbreak of urushiol-induced allergic contact dermatitis; and drying the solution to form a polyureathane linked copolymer coating that inhibits growth of the onychomycosis or urushiol-induced allergic contact dermatitis, and/or mitigates the deleterious effects thereof. In one embodiment, the primary diamine may be mixed with a secondary diamines in an oligomeric, stoichiometrically balanced blend.
  • In another embodiment, a composition for the topical treatment of onychomycosis and urushiol-induced allergic contact dermatitis comprises a mixture of a primary diamine in a volume ratio ranging from about 3.6% to about 12.2% v/v of the total solution; a chain extension reagent in a volume ratio ranging from about 2.0% to about 6.2% v/v of the composition; and a stabilizing carrier in an amount sufficient to prevent formation of a gel or solid prior to removal of a portion of the stabilizing carrier.
  • BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 is a chemical diagram of polytetramethylene oxide-di-p-amino benzoate.
  • FIG. 2 is a functional block diagram depicting a polymer chain in three-dimensional space.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The formulations for topical treatments for onychomycosis and urushiol-induced allergic contact dermatitis are essentially developed as a single, sequential step mixing process wherein the desirable properties of the formulations are obtained by blending the desired reactants in a single sequential step procedure. For example, the following blend/mixture of components has been determined effective in treating onychomycosis or urushiol-induced allergic contact dermatitis:
  • 1) A primary diamine, or an oligomeric, stoichiometrically balanced blend of primary and secondary diamines, as a pre-polymer.
  • 2) Specific modified diphenylmethane diisocyanates used for polymer chain extension in order to obtain a cured polyureathane/urea polymer.
  • 3) A primary carrier solvent/reactant, such as for example acetone aka propanone.
  • 4) Optionally, a secondary carrier solvent/reactant, such as for example mineral spirits.
  • 5) Optionally, additives, such as a polyether oxyalkylene polyol to reactively support the carrier solvent/reactant(s), and/or an amine-functional reactive partner (resin) to crosslink with aliphatic polyisocyanates for polymer chain extension.
  • These components, in stoichiometrically balanced volume ratios, provide treatment devices with a range of material characteristics ably suited for various application requirements. The sequential mixing process is normally done at ambient conditions of 70-80 Fahrenheit, about 750-760 mm Hg, and relative humidity of 50-65%.
  • The mixture of these components to obtain a urea-linked polyureathane co-polymer is governed by the well-principled science of stoichiometric chemistry. Stoichiometric chemistry mix requirements for compatible polymeter components of various average molecular weight and various NCO % content are well known and practiced by those skilled in the science of polymer chemistry.
  • Suitable materials for each of these classifications are discussed below, followed by a description of the suspected mechanics underlying the delayed polymerization exhibited by the present invention. Following a discussion of the mechanics of the present invention as a device for treating onychomycosis and skin conditions such as urushiol-induced allergic contact dermatitis, specific examples of commercially available suitable components are listed, as are examples detailing actual experimental results.
  • Diamines
  • In one or more embodiments, an oligomeric blend of diamines developed for the present invention consists of a primary diamine and a secondary diamine. In other embodiments, a single diamine is used. The amine functionality is capped onto the ends of the soft segment. Chain extension, or polymerization, is accomplished by using MDI, modified forms of monomeric MDI, or MDI containing resins as the hard segments. Elastomers prepared from such generic formulations exhibit the best overall physical properties of liquid-phase cast elastomers, although other soft segments can be used—polyether, polyester, polycarbonate, or polypropylene glycol. TDI-amine elastomers contain urethane and urea linkages, while MDI-polyol elastomers contain only urethane linkages. MDI-amine elastomers contain only polyureathane/urea linkages.
  • Isocyanates
  • A suitable polyisocyanate for use in the polymer chemistry system of the present invention is one that is conventionally employed in the production of polyurethanes.
  • Examples of monomeric polyisocyanates useful herein include polyisocyanates and polyisothiocyanates which are PAPI-1 (a polyaryl polyisocyanate as defined in U.S. Pat. No. 2,683,730), tolylene diisocyanate “TDI”, triphenylmethane-4,4′4″-triisocyanate, benzene-1,3,5-triisocyanate, toluene-2,4,6-triisocyanate, diphenyl-2,4,4′-triisocyanate, hexamethylene diisocyanate, xylylene diisocyanate, chlorophenylene diisocyanate, diphenylmethane-4,4′-diisocyanate, naphthalene-l,5-diisocyanate, xylene-alpha, alpha'-diisothiocyanate, 3,3′-dimethyl-4,4′biphenylene diisocyanate, 3-3′dimethoxy-4,4′-biphenylene diisocyanate, 2′, 3,3′-dimethyl-4, 4′-biphenylene diisocyanate, 5,5′-tetramethyl-4,4′biphenylene diisocyanate, 2,2′, 5,5′-tetramethyl-4,4′biphenylene diisocyanate, 4,4′methylenebis(phenylisocyanate), 4,4′-sulfonylbis (phenylisocyanate), 4,4′-methylene di-orthototylisocy anate, ethylene diisocyanate, ethylene diisothiocyanate, trimethylenediisocyanate and the like. Mixtures of any one or more of the above mentioned organic isothiocyanates or isocyanates may be used as desired.
  • Additionally suitable are mixtures of TDI such as a mixture (80/20 by weight) of 2.4-toluene diisocyanate and 2,6 toluene diisocyanate or a mixture (65/35 by weight) of 2,4-toluene diisocyanate and 2,6-toluene diisocyanate; tetramethylene diisocyanate; hexamethylene diisocyanate; xylene diisocyanate; 1,5-na.pththylene diisocyanate; 1,4-phenylene diisocyanate; 4,4′-'diphenylmethane diisocyanate (MDI) (Upjohn's ISONATE® 125M); 4,4′4″-triphenylmethane triisocyanate; and 3,3′-dimethyl-4.4′-diphenylmethane diisocyanate. Aliphatic diisocyanates such as the C36 aliphatic diisocyanate derived from the dimer of ricinoleic acid can be suitably employed and are commercially available, for example, as DDI-1410 (Henkel Corporation, Resin Division, Minneapolis. Minn.). The polyisocyanates hereof are known polyisocyanates in the field of polyurethane technology and can be employed singly or in admixture. Other examples of such polyisocyanates can be found, for example, in The Development and Use of Polyurethane Products, E. N. Doyle, McGraw-Hill Book Company, page 27 (1971) and Polyurethane Handbook, Gunter Oertel Hauser. Gardner Press (1994).
  • Preferred polyisocyanates for employment in the process of the present invention are polyisocyanate materials in a liquid form at ambient temperatures, e.g., a liquid MDI product as disclosed in U.S. Pat. No. 3.394,164. These materials facilitate the production of polymeric products from normally liquid oligomeric aminobenzoic acid esters or amides and obviate the requirement of melting a solid polyisocyanate as a prerequisite to providing a suitable reaction mixture. Suitable liquid polyisocyanate materials are known and include, for example, polymeric MDI (4,4′-diphenylmethane diisocyanate) products obtained as by-products from the synthesis of MDI.
  • In the production of MDI by the condensation of aniline with formaldehyde and the conversion of amino to corresponding isocyanate groups, a content of the initially formed bis-adduct of aniline and formaldehyde reacts further with the reaction mixture to form polymeric aniline derivatives which are in turn converted to isocyanates. Typically, such polymeric derivatives will have a functionality of from about 4 to about 15, for example, about 10 isocyanate groups per molecule. Products containing such polymeric polyiscocyanates in the form of a pot residue after removal of pure MDI by distillation can be utilized. Similarly, polyisocyanate products comprising such polymeric polyisocyanate species in admixture with pure MDI, i.e., the undistilled reaction mixture, can be employed. Polymeric MDI products can be employed herein to advantage and are commercially available under such trade designations as RURBINATE® M, RURBINATE® LF-168 and RURBINATE® LF-209 (available from Rubicon Chemicals Inc. Geisman. La.) and PaPI 27, PaPI 135, PaPI 580 and PaPI 901 (available from the Upjohn Company, Kalamazoo, Mich.).
  • Another liquid polyisocyanate material which can be employed where crosslinking is desirably introduced into the polymeric products hereof comprises an admixture of MDI and a tri-functional cycloaddition product of MDI. An admixture of MDI and a trifunctional cycloadduct having the following structure, where R is
    Figure US20060216267A1-20060928-C00001

    can be employed:
    Figure US20060216267A1-20060928-C00002
  • Such an admixture is available under the designation “Liquid MDI, Isonate 143L” (The Upjohn Company, Kalamazoo, Mich.).
  • To reiterate, in addition to the preferred MDI, modified forms of monomeric MDI or MDI-containing resins, any suitable organic diisocyanate may be used in the process of this invention such as, for example, aliphatic diisocyanates, aromatic diisocyanates, alicyclic diisocyanates, and heterocyclic diisocyanates including such as, for example, ethylene diisocyanate, ethylidene diisocyanate, propylene diisocyanate, butylene diisocyanate. cyclopentylene-1,3-diisocyanate, cyclohexylene-l,4-diisocyanate, cyclohexylene-1,2.diisocyanate, 2,4-tolylene diisocyanate, 2,6-tolylene diisocyanate, 4,4′-diphenylmethane diisocyanate, 2,2-diphenylpropane-4,4′-diisocyanate, p-phenylene diisocyanate, m-phenylene 15 diisocyanate, xylylene diisocyanate, 1,4-napthylene diisocyanate, 1,5-naphthylene diisocyanate, diphenyl-4,4′diisocyanate, azobenzene-4,4′-diisocyanate, diphenylsulfone-4,4′-diisocyanate, dichlorohexamethylene diisocyanate, tetramethylene diisocyanate, pentametylene diisocyanate, hexamethylene diisocyanate, 1-chlorobenzene-2,4-diisocyanate, furfurylidene diisocyanate, triphenyl methane triisocyanate and the like.
  • Other examples of suitable organic diisocyanates include 1,4-tetramethylene diisocyanate, 1,6-hexamethylene diisocyanate, 2,2,4-trimethyl-1.6-hexamethylene diisocyanate, 1,12-dodecamethylene diisocyanate, cyclohexane-1,3-and-1,4-diisocyanate, 1-isocyanato-2-isocyanatomethyl cyclopentane, 1-isocyanato-3-isocyanatomethyl-3,5,5-trimethyl-cyclohexane (isophorone diisocyanate or IPDI), bis-(4-isocyanatocyclohexyl)-methane, 2,4′dicyclohexyl-methane diisocyanate, 1,3- and 1,4-bis(isocyanatomethyl)-cyclohexane, bis-(4-isocyanato-3-methyl-cyclohexyl)-methane, α,α,α′,α′-tetramethyl-1,3-1-isocyanato-1-methyl-4(3)-isocyanatomethyl cyclohexane, 2,4-, 1,3- and/or 1,4-phenylene diisocyanate, 2,4- and/or 2,6-toluylene diisocyanate, 2,4- and/or 4,4′-diphenyl-methane diisocyanate, 1,5-diisocyanato naphthalene and mixtures thereof. Aromatic polyisocyanates containing 3 or more isocyanate groups such as 4,4′,4″-triphenylmethane diisocyanate.
  • In accordance with the present invention, the polyisocyanate component can be in the form of an NCO prepolymer or a polyisocyanate adduct, more preferably a polyisocyanate adduct. Suitable polyisocyanate adducts are those containing, isocyanurate, uretidone, biuret, urethane, allophanate, carbodiimide and/or oxadiazinetrione groups. The polyisocyanates adducts have an average functionality of 2 to 6 and an NCO content of 5 to 30% by weight. The isocyanato-isocyanurateg generally have an average NCO functionality of 3 to 3.5 and an NCO content of 5 to 30%, preferably 10 to 25% and most preferably 15 to 25% by weight.
  • Preferred polyisocyanate adducts are the polyisocyanates containing isocyanurate groups, biuret groups or mixtures of isocyanurate and allophanate groups.
  • The NCO prepolymers, which may also be used as the polyisocyanate component in accordance with the present invention, are prepared from the previously described monomeric polyisocyanates or polyisocyanate adducts, preferably monomeric diisocyanates, and organic compounds containing at least two isocyanate-reactive groups, preferably at least two hydroxy groups. These organic compounds include high molecular weight compounds having molecular weights of 400 to about 6,000, preferably 800 to about 3,000, and optionally low molecular weight compounds with molecular weights below 400. The molecular weights are number average molecular weights (Mn) and are determined by end group analysis (OH number).
  • With regard to the organic diisocyanates, the prepolymers and the polyisocyanate adducts, reference is made to U.S. Pat. No. 5,516,873, which is incorporated by reference hereinto in its entirety.
  • Carrier Solvent/Reactants
  • A suitable stabilizing carrier is one which will completely dissolve the selected aromatic diamine derivative and the selected polyisocyanate when they are combined to form a reaction solution but which will prevent the resultant polymeric reaction product, i.e. the polyurea, from solidifying or gelling out of the reaction solution. In other words, the stabilizing carrier either prevents the normally near instantaneous reaction between the isocyanate group and the amino group or prevents the resultant reaction product, e.g., polyurea, from solidifying or gelling until such time as a portion of the stabilizing carrier or solvent is removed from the resultant solution, e.g., as by evaporation.
  • A suitable stabilizing carrier comprises a stabilizing solvent selected from:
  • (a) an aldehyde or ketone of the formula
    Figure US20060216267A1-20060928-C00003
  • where R4 and R5 are independently of each other hydrogen and lower alkyl or R4 and R5 are joined to form a five or six membered ring; where the term “lower” is as previously defined; and where the term “alkyl” is as previously defined;
  • (b) an ester having the formula
    Figure US20060216267A1-20060928-C00004
  • where R6 and R7 are loweralkyl (as previously defined) and R7 additionally is H and loweralkoxy where the term “lower” is as previously defined and the term “alkoxy” is as previously defined;
  • (c) ortho, meta-or para-dimethylbenzene;
  • (d) N-methylpyrrolidone;
  • (e) Solvesso solvent;
  • (f) a petroleum hydrocarbon;
  • (g) a lactone of the formula
    Figure US20060216267A1-20060928-C00005

    (loweralkylene)
    where “lower” and “alkylene” is as previously defined; such as y-butyrolactone; and
  • a mixture of any of the foregeoing solvents; combined with at least one polyol of the formula
    HO-loweralkylene-OH
    where “lower” and “alkylene” is as previously defined.
  • Some suitable aldehydes and ketones, for example, include acetone, methyl ethyl ketone, methylisobutylketone, N-methylcyclohexanone, acetaldehyde, propionaldehyde, butryaldehyde and isobutyraldehyde. Some suitable solvents of formula (b) include methyl acetate, ethyl acetate, butyl acetate, and methoxy propyl acetate. Some suitable polyols include, for example, polyglyols of the formula
    Figure US20060216267A1-20060928-C00006
  • where p is an integer equal to 1 to 14, as for example when p is equal to 1 to 3, such compounds as ethylene glycol, propylene glycol, butylene glycols, such as 1,3-, 1,4-, and 2-3-butylene glycol, and alkylene glycols having 5 to 9 carbon atoms; when n is 4 or greater, polyglycols of an average molecular weight of about 600, such as polyethylene glycol 200, polyethylene glycol 400 and polyethylene glycol 600. It is to be understood that a mixture of the stabilizing solvents, e.g. aldehydes and ketones, can be employed, as well as a mixture of polyols, e.g., a mixture of ethylene glycol and propylene glycol.
  • The selected aromatic diamine derivative and the selected polyisocyanate components are added to the stabilizing carrier solution to form a reaction solution. Conventionally, these reaction components are combined in the stabilizing carrier in solution in substantially equivalent proportions, that is in amount of the polyisocyanate of about 0.9 to 1.2 equivalents per equivalent of the first component of oligomeric aromatic diamine derivative, based upon the isocyanate groups and amino groups, respectively, of the polyisocyanate and oligomeric diamine derivative reactants. Typically, from about 1.0 to about 1.15 equivalent of polyisocyanate material per equivalent of the first component e.g., diamine derivative is employed.
  • Preferably, the primary reactants, e.g. oligometrice diamine derivative, and the polyisocyanate are combined in a volume ratio whereby the isocyanate is in excess to the ester or amide or diamine and is expressed in the following manner: 100 0.95 × 1 Total Equivalent Weight of the first component e . g . the oligomeric primary diamine × percent volume of the polyisocyanate second component
    which gives the parts of the polyisocyanate per 100 parts of the first reactant e.g. the oligomeric diamine derivatives.
  • The amount of carrier agent employed is one which is sufficient to dissolve the first reactants e.g. the oligomeric diamine derivatives, and the polyisocyanate second reactant and maintain the reaction product thereof, i.e., the polyurea, in solution without the precipitation out or gelling of the polyurea product. Typically, the amount of stabilizing carrier employed is about 10 to 80% of the total reaction solution volume. Typically the amount of the stabilizing solvent, e.g. aldehyde and/or ketone, employed with at least one polyol is in the ratio of 10 to 80 parts of solvent to one part of polyol. The amount of stabilizing solvent, e.g. acetone, is adjusted depending upon the viscosity desired for specific application requirements, e.g. for maximum penetration and an ultrathin coating thickness for glass, plumbing fixtures, furniture coatings, to a heavy gauge coating thickness for substrates having heavy chemical or environmental corrosion exposure. Typically, the reaction product viscosity will range from about 3.5 centipoise to about 1800 centipoise at room temperature.
  • The oligomeric diamines in the stabilizing carrier typically react with the polyisocyanate at room temperature; however, the reaction solution can be heated to affect reaction.
  • The resultant reaction solution is a ‘single pot’ polyurea composition that can be stored for a long period of time, e.g. 6-9 months at 25° C. without exhibiting any instability or gelling out of the polyurea. Accordingly, this single pot composition can be applied in any manner for a synthetic polymer process, e.g., casting, molding, spraying, etc., where, after application, the single pot composition is treated, e.g. by heating, vacuum evaporation, etc., to remove at least a portion of the stabilizing carrier, leading to the formation of a solid, cured polyurea material.
  • Additives
  • While the process and the single pot formulation permits the production of polymeric materials without the use of blocking agents, end-capping chemical modifications or thermally activated catalysts, e.g. caprolactum, B-carbonyl compounds (such as ethyl aceto acetate, ethyl malonate), alcohols and oximes; polymerization additives of various types employed in the manufacture of polymeric products can desirably be employed. For example, such polymerization agents as catalysts, ultraviolet absorbers, fillers, plasticizers, blowing agents, etc., can be employed where desired.
  • Typically a flow and leveling agent polymerization additive is employed. Preferably such additive comprises a glycidyl-ester of neo decanoic acid, of the formula
    Figure US20060216267A1-20060928-C00007
  • where the R10, R11, R12 are independently of each other H and lower alkyl where the sum of each alkyl group of R10, R11, and R12 does not exceed 8 carbon atoms.
  • Other flow and leveling agents include the diglycidyl either of 1.4-butane diol, the diglycidyl ether of neopentyl glycol, the poliglycidyl ether of aliphatic polyols, phenyl glycidyl ether, nonyl phenyl glycidyl ether, C9-C18 glycidyl ether of castor oil, trimethyol ethane of triglycidyl ether and the ester forms of the aforementioned ethers. These ethers and esters are commercially available from the Shell Chemical Company and are designated as HELOXY®. The glycidyl neodecanoate is commercially available from Exxon Chemical Company and is known as GLYDEXX N®-10.
  • Additionally, employed is an ultraviolet (UV) light absorber such as benzotriazoles, e.g. benzotriazoles disclosed in U.S. Pat. Nos. 3,004,896 and 3,189,615. Such benzotriazoles are commercially available from Ciba Geigy as Tinuyin® products, such as Tinuvin® P, (2-(2H-benzotriazol-2yl))-4-methylphenol); Tinuvin® 1130, comprising about fifty-two weight percent of poly{oxy-1,2-ethanediyl), α-(3-(3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxyphenyl)-oxopropyl)-ω-hydroxy, of the formula
    Figure US20060216267A1-20060928-C00008

    having an average molecular weight of 637, about thirty-five weight percent of poly(oxy-1,2-ethanedlyl), α-(3-(3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxyphenyl)-1-oxopropyl-ω-(3-(3-2H-benzotrazol-2-yl)-5-(1,1-diamethylethyl)-4-hydroxyphenyl)-l-oxopropyoxy),
  • of the formula
    Figure US20060216267A1-20060928-C00009

    having an average molecular weight of 975, and the remainder (about thirteen weight percent of polyethylene glycol (300 molecular weight), which is used to functionalize the Tinuvin® 1130; Tinuvin® 292 and Tinuvin® 328, [2-(2′-hydroxyl-3, 5′-di-tert-amylphenyl)benzotriazole].
  • Finally, an antioxidant is employed. A preferred antioxidant is 3,5-di-tert-butyl-hydroxycinnamate, known as IRGANOX® 1076, commercially available from Ciba Geigy.
  • A preferred UV stabilizer/antioxidant additive composition comprises about 70-75 weight percent of Tinuvin® 1130, 10-15 weight percent IRGANOX® 1076 and 10-20 weight percent of Tinuvin® 328.
  • The concentration of the additives, e.g. UV stabilizer, antioxidant, leveling agent, etc. of the total formulation will, of course, depend upon the desired use of the formulation and will be varied accordingly in a manner well known to those skilled in the art. Typically, where the reactants are HUNTSMAN D-2000 and ISONATE® 2143L or BAS7 218, the carrier solvent is acetone and the leveling agent GLYDDEX® N-10 is employed, the polyol component of the stabilizing carrier in the reaction solution is present in an amount which is in the ratio of the oligomeric diamine derivatives to the polyol of 5 to 2.66 to 1, preferably between 4.25 and 1.75 to 1, and, most preferably 4.0 to 1.
  • If a mixture of polyols is employed, e.g., ethylene glycol and propylene glycol, each polyol preferably should be present in equal amounts. If each polyol of the mixture of polyols is not present in equal amounts in making up the ratio of diamine to polyol, then the cure time and storage time will vary. For example, where a mixture of ethylene glycol (“EG”) and propylene glycol (“PPG”) is employed and the ratio of EG/ISONATE® 2143L to PPG/ISONATE® 2143L (“RATIO”) is greater than 1, then the following cure times are obtained:
    RATIO CURE TIME (25°)
    1.0 1.5-2 hours
    1.25 6-7 hours
    2.0 28-32 hours
  • Additionally, typically, the ratio of N-10/218 is equal to or less than the ratio of EG+PPG/218. If it is greater, then the dry times of the coatings resulting from the reaction solution are lengthened. When the ratio is less than 1, the flow and spreadability of the reaction solution is reduced. The ratio range is typically 0.72 to 1.3, preferably 0.85 to 1.15, and most preferably 1.0 for N-10/218 to EG+PPG/218.
  • Finally, the ratio of EG+N-10/2143L to PPG+N-10/2143L is typically 1, whereby an optimum drying time of about 45 minutes to one hour and fifteen minutes at 25° C. is obtained. Ratios of less than or more than 1 typically produce reaction solutions with proportionate increases in drying times.
  • Another ratio which is considered is the ratio of EG/N-10 and PPG/N-10 which typically are equal to each other as well as equal to twice that of (EG+PPG)/2143L. Typically, the ratio of EG/N-10 to PPG/N-10 is 0.8 to 1.42, preferably 0.92 to 1.2 and most preferably 1.0.
  • Mechanics of Suspended Polymerization
  • It is hypothesized that the resultant single pot polyurea formulation having a very long shelf life without any solidification or gelling of the polyurea, e.g., 9 to 12 months at a temperature of 5 to 45° C., is due to an in situ ionic shielding action. This ionic shielding action is only a hypothesis and is not to be a limiting factor of the subject invention. The in situ ionic shielding action is hypothesized to be obtained by the reaction of the stabilizing solvent, e.g., acetone, and the polyol, e.g., a mixture of ethylene glycol and propylene glycol. This in situ reaction and its continued maintenance while in a sealed and lidded container is believed to be the electrochemical basis for being able to provide a single pot, polyurea based, elastomer polymer composition having long term shelf life, with constant clarity, fluidity and drying time factors. It is hypothesized that the reaction between the stabilizing solvent, e.g. acetone, and the polyol, e.g., a mixture of ethylene glycol and propylene glycol, produces an excess of hydrogen ions which interact with the primary amine groups of the oligomeric aromatic diamine derivative, thereby preventing reaction thereof with the polyisocyanate until a portion of the stabilizing carrier is removed, e.g., by evaporation. The basis of this belief is presented below.
  • If the reaction rate depends on electrophilic (i.e., electron seeking) attack on the aromatic ring, then substituents that withdraw electrons from the ring will decrease electron density in the ring—and therefore slow down the reaction. Conversely, substituents that donate electrons will speed up the reaction. This reactivity pattern is observed with all electrophilic aromatic substitution reactions.
    Glycols—Ethylene and Propylene (DIOLS)
    Figure US20060216267A1-20060928-C00010
  • Alcohols are weak acids. The hydroxyl group can act as a proton donor:
    Figure US20060216267A1-20060928-C00011
  • Essentially, donating protons is equivalent to withdrawing electrons, corresponding to reactivity reduction.
    Figure US20060216267A1-20060928-C00012
  • The portion of the formula to the right-hand side of the dashed line represents the elimination of the C═O double bond in the acetone molecule. Acetone-ethylene glycol ketal can be presented as a cyclic aromatic hydrocarbon.
  • In reactions in which a constituent is a particular solvent (primarily for viscosity purposes) substrates (solvents) that donate electrons are called donor solvents, while substrates that extract electrons are called acceptor solvents. Resonance effects being equal, the reactivity of a donor radical will always be greater with an acceptor solvent than with a donor solvent. Acetone is classified as an acceptor solvent
  • If one applies the action of donor and acceptor solvents, one can understand the cause of the reaction between ethylene glycol:
    Figure US20060216267A1-20060928-C00013

    and acetone:
    Figure US20060216267A1-20060928-C00014

    producing a + hydrogen ion, while at the same time eliminating the C═O double bond in acetone. It is also reasonable to assume that the constituent reactivity of ethylene glycol is considerably greater—insofar as providing + H ions in acetone, an acceptor solvent. In similar manner, the reaction of constituent propylene glycol behaves in an analogous fashion.
  • The reactivity of the —N═C═O— group is mainly determined by the pronounced positive (+) character of the C-atom in the cumulative double-bond sequence consisting of nitrogen, carbon, and oxygen. The positive charge at the C-atom becomes obvious if one looks at the resonance structure, which also indicates how substituents at the radical which bears the NCO group can influence this reactivity.
    Figure US20060216267A1-20060928-C00015
  • The negative charge can be delocalized, or transferred in R, if R stands for an aromatic radical.
  • Substituents on the aromatic ring show the known influences on the positive character of the NCO group. To wit, electron-withdrawing substituents in PARA- or ORTHO-positions increase the reactivity of the NCO-group, and electron-donating substituents lower the reactivity of the NCO group.
  • At this point, the following possible inhibition mechanism, or equilibrium reaction, is to be considered as a likely—and most reasonable—explanation, based on all previous stated facts.
  • Fact 1. The reaction of the solvent acetone with both ethylene glycol
    Figure US20060216267A1-20060928-C00016

    and propylene glycol:
    Figure US20060216267A1-20060928-C00017

    produces an excess of H+ ions.
  • Fact 2. The mobility of these reaction H+ ions is approximately 103× greater than the mobility of the NCO groups in the same common solvent—acetone.
  • Fact 3. The R radical of P-1000 (also P-250 and P-650) is the primary amine
    Figure US20060216267A1-20060928-C00018

    located at both ends of the oligomeric backbone diamine. See FIG. 2. Note that electrophilic substitution (and resonant replacement) is a predominant feature of reactions with benzene and delocalized π (pi) electrons on the benzene ring.
  • Fact 4. As discussed above, a negative charge can be delocalized or transferred in an aromatic radical. The primary amine, being an aromatic radical, bears a delocalized negative (−) change, which in terms of the order of magnitude (×3) of the glycols-acetone reaction, effectively neutralizes the negative (−) charged radicals in a manner so effective as to virtually reduce to zero the positive charge affinity of the carbon atom in the NCO group to react with the delocalized negative charge on the aromatic radical, the primary amine, principally because of the vast difference in solvent mobility. In other words, the highly mobile H+ ions literally “lock-up” the amine radicals well before the virtually immobile NCO-group molecules can find any un-neutralized negative (−) radicals.
  • Fact 5. When the 1-part mix is applied as a coating or sealant, e.g., over a toe nail, fingernail, or skin, the rapid evaporation of the acetone terminates the H+ ion reaction of the liquid acetone/glycols, leaving in solution primarily the oligomeric diamine/NCO reactants. In this condition—acetone removed by evaporation—the NCO/oligomeric diamine constituents experience initiation of polymerization, and continue until completely polymerized into a polyurea elastomer.
  • Fact 6. Hydrodynamic volume-solvent effects and molecular weight analysis: Once a polymer-solvent system has been selected, another consideration is how the polymer molecules behave in that solvent. Particularly important from the standpoint of molecular weight determinations is the resultant size, or hydrodynamic volume, of the polymer molecules in solution.
  • Assuming that polymer molecules of a given molecular weight are fully separated from one another by solvent, the hydrodynamic volume will depend on a variety of factors, including
  • A) Interactions between solvent and polymer molecules;
  • B) chain branching;
  • C) conformation effects arising from the polarity and steric bulk of the substituent groups; and
  • D) restricted rotation caused by resonance, for example, of the type common to polyamides and polyamines:
    Figure US20060216267A1-20060928-C00019
  • Because of Brownian motion, molecules are changing shape continuously. Therefore, any method of trying to predict molecular size (and subsequently molecular weight) must necessarily be based on statistical methods and average dimensions. If a molecule were fully extended, its size could easily be computed from knowledge of bond lengths and bond angles. Such is not the case, however, with most polymers. Because of this lack of exact knowledge of bond lengths and bond angles, size is generally expressed in terms of the following. For a linear polymer, {overscore (r)}2=mean square average distance between chain ends. For a branched polymer, {overscore (s)}2=square average radius of gyration about the center of gravity.
  • FIG. 2 illustrates the meaning of r and s from the perspective of a coiled structure of an individual polymer molecule having its center of gravity at the origin. The average shape of the coiled molecule is spherical. The greater the affinity of solvent for polymer, the greater the size of the sphere, or, in corollary fashion, the greater the value of s. That is, the greater the affinity of solvent for polymer, the greater the size of the sphere, i.e., the hydrodynamic volume. When solvent-polymer integration decreases, intramolecular interactions become more important, leading to hydrodynamic volume contraction.
  • In order to discuss the quantitative aspects of hydrodynamic volume parameters as related to solvent-polymer interaction, it is appropriate to define terms. Both r and s must be defined in terms of two factors:
      • A) ro and so: an unperturbed dimension; and
      • B) α: a volume expansion factor.
  • These definition permit the following relations:
    {overscore (r)}2=r0 2α2
    {overscore (s)}2={overscore (s)}0 2α2
  • The unperturbed dimensions, ro and so, refer to the size of the macromolecule, exclusive of solvent effects. It is established from a combination of free rotation and intramolecular xxxx and polar interaction. The expansion factor α is defined in terms of interactions between solvent and polymer. For a linear polymer, {overscore (r)}2=6{overscore (s)}2. Since α = ( r _ 2 ) 1 / 2 ( r 0 2 ) 1 / 2
    it is a conclusion that a will be >1 in a “good solvent” and the actual perturbed dimensions, r and s, will both have larger values than their corresponding “unperturbed” dimension values. The greater the value of α for a particular solvent-polymer combination, the “better” the solvent. For the special case where α=1, the polymer assumes its “unperturbed” dimensions, and behaves as an “ideal” statistical coil.
  • Since solubility properties vary with temperature in a given solvent, α is temperature dependent. For a specific polymer in a specific solvent, the lowest temperature at which α=1 is coiled the theta (⊖) temperature, (or flory temp.) and that solvent is then called a theta solvent. Additionally the polymer is said to be in a theta state. It is usual to define the theta of a polymer as that state in which the polymer is on the brink of becoming insoluble.
  • The Present Invention as a Treatment Device for Onychomycosis and Urushiol-Induced Allergic Contact Dermatitis
  • The polymer chemistry-based formulations of the present invention exhibit many properties and characteristics that make them suitable as a topically applied device for the treatment of onychomycosis and skin conditions such as urushiol-induced allergic contact. They are non-toxic; non-human carcinogenic; hydrophilic in a liquid state and hydrophobic in a cured state; and elastomeric. The formulations are non-water based; resistant to solar ultraviolet exposure degradation; and exhibit a non-degraded, long-term effective elastomeric thermal stress response over a tested range of −80 degrees F. to +225 degrees F.
  • The polymer chemistry-based formulations are chemically classified as a polyureathane/urea cross-linked polymer. They exhibit physical and chemical properties of a thermoset polymer; exhibit uniform structural characteristics, i.e. isotropic with uniform tensile strength and elastomeric properties in both longitudinal and radial directions; and are chemically inert to a large number of corrosive chemical agents. The formulations are biologically inert; long term (one year) immersion of wood treated with the formulations in both water and soil produced no detectable alterations in either physical or chemical properties.
  • A particular property of the formulations, believed to be responsible for their efficacy as topical devices for the treatment for onychomycosis and skin conditions such as urushiol-induced allergic contact dermatitis, is that when applied as a surface coating of approximately 0.003-0.007 inches thick, the formulations allow transmission of water vapor, but not water liquid. That is, thin topical coatings of the formulations are “water proof,” or impervious to moisture. It is believed that this property “seals off” dermatophytes beneath a nail from, e.g., the moisture of sweat when trapped in socks and shoes, or from showers, humidity, and other environmental exposure to moisture. The elastomeric polymer device itself is nonsupportive of fungal or bacterial growth, and by preventing the absorption of environmental moisture, may preclude the growth of fungi such as dermatophytes.
  • Similarly, a coating of the formulations over an outbreak of urushiol-induced allergic contact dermatitis seals off urushiol-impregnated skin cells from environmental moisture, while allowing water vapor, such as perspiration, to pass. The topical device also dramatically reduces itching associated with urushiol-induced allergic contact dermatitis, although the precise mechanism of this benefit is not thoroughly understood.
  • In thin coatings on nails and skin, the formulations exhibit very fast drying times, and form a tough yet pliable watertight seal. The elastomeric property of the coatings prevents them from cracking and peeling as the skin (or nail) is deformed. The formulations are exceptionally amenable to blending with a large variety of organic based dyes and colorants; most notable are the colorants manufactured by HULS AMERICA, INC., known as the 844 Colorant System. Thus, in the case of treating onychomycosis, the formulations may be died and used in lieu of fingernail and toe nail paint. In the case of urushiol-induced allergic contact dermatitis, the formulations may be used without pigments, in which case they dry to a clear or translucent tone, or they may be mixed with various pigments to blend to skin tones.
  • Specific Formulations
  • The preferred elastomers for the practice of the present invention are obtained by formula ratio variations (i.e., stoichiometrically balanced) of the presently used components; these components, their chemical descriptions, and commercial product information are described below. Those of skill in the art will readily recognize that other components may advantageously be used, and the present invention is not limited to use of any of these particular components.
  • 1) First Diamine
  • a) Manufactured by Huntsman Petrochemical Corp., Houston, Tex.
  • b) Chemical family. CAS #9046-10-0-Polyoxypropylenediamine
  • c) Description/Use: Chemical Intermediate
  • d) Chemical name: Poly[oxy(methyl-1,2-ethanediyl)], alpha-(2-aminomethylethyl)-omega-(2-aminomethylethoxy)-
  • e) Commercial name: Jeffamine® D-2000
  • 2) Second Diamine
  • a) Manufactured by Arch Chemicals, Inc., Norwalk Conn.
  • b) Chemical family. CAS #9046-10-0-Polyoxypropylenediamine
  • c) Description/Use: Chemical Intermediate
  • d) Formula: (C3H6O)nC6H12N2O
  • e) Chemical name: Poly[oxy(methyl-1,2-ethanediyl)], alpha-(2-aminomethylethyl)-omega-(2-aminomethylethoxy)-
  • f) Commercial name: POLY-A® 27-2000
  • 3) Third Diamine
  • a) Manufactured by Dorf Ketal Chemicals LLC, Stafford, Tex.
  • b) Chemical family. CAS #5285-60-9 Aromatic Diamine
  • c) Description/Use: Chain extender for polyurethane elastomers
  • d) Chemical name: N,N′-dialkylamino-diphenylmethane; 4,4′-Bis(sec-butylamino)diphenylmethane
  • e) Commercial name; Unilink 4200
  • 4) Fourth Diamine
  • a) Manufactured by Air Products and Chemicals, Inc., Allentown, Pa.
  • b) Chemical family. CAS #54667-43-5 Oligomeric diamine
  • c) Description/Use: Polymer-chain Extender
  • d) Chemical name: Polytetramethyleneoxide-di-p-aminobenzoate;
  • e) Commercial name; Versalink® P-1000
  • 5) First Isocyanate
  • a) Source: Huntsman Chemicals, Houston, Tex.
  • b) Chemical family: CAS. No. 26447-40-5
  • d) Description/Use: Polymer chain extension
  • e) Formula description: Modified MDI
  • c) Commercial name: Rubinate® 9433
  • 6) Second Isocyanate
  • a) Source: Huntsman Polyurethanes, West Deptford, N.J.
  • b) Chemical family: Modified Diisocyanate
  • c) Description/Use: Water-Emulsifiable MDI
  • d) Formula description: Polymeric Diphenylmethane Diisocyanate and Modified MDI
  • e) Commercial name: Rubinate® 9259
  • 7) Third Isocyanate
  • a) Source: Huntsman Polyurethanes, West Deptford, N.J.
  • b) Chemical family: Modified Diisocyanate
  • c) Description/Use: Water-Emulsifiable Crosslinker
  • d) Formula description: Polymeric Diphenylmethane Diisocyanate and Modified MDI
  • e) Commercial name: Rubinate® 9236
  • 8) Fourth Isocyanate
  • a) Source: Dow Chemical Company, Midland, Mich.
  • b) Chemical family: Polycarbodiimide-modified Diphenylmethane Diisocyanate
  • c) Description/Use: Polymer chain extension
  • d) Formula description: Diphenylmethane Diisocyanate (MDI) containing Methylene Bisphenyl isocyanate, Diphenylmethane Diisocyanate (homopolymer) and Triethyl Phosphate
  • e) Commercial name: Isonate® 143L Modified MDI
  • 9) Fifth Isocyanate
  • a) Source: BASF Corporation, Mount Olive, N.J.
  • b) Chemical family: Aromatic isocyanate
  • c) Description/Use: Polymer chain extension
  • d) Formula description: Diphenylmethane-4,4′-diisocyanate (MDI), Modified MDI, and MDI Mixed Isomers
  • e) Chemical name: Modified MDI
  • f) Commercial name: Lupranate® 81 Isocyanate
  • 10) Sixth Isocyanate
  • a) Source: BASF Corporation, Mount Olive, N.J.
  • b) Chemical family: Aromatic Isocyanate
  • c) Description/Use: Polymer chain extension
  • d) Formula description: 4,4′ Diphenylmethane Diisocyanate (MDI), Modified MDI, and MDI Mixed Isomers
  • e) Chemical name: Carbodiimide Modified MDI
  • f) Commercial name: No. 218 Isocyanate
  • 11) Seventh Isocyanate
  • a) Source: Bayer Corp., Pittsburgh, Pa.
  • b) Chemical family: Aliphatic Polyisocyanate
  • c) Description/Use: Polymer chain extension
  • d) Formula description: 1,6-Hexamethylene Diisocyanate Based Polyisocyanate
  • e) Chemical name: Polymeric Hexamethylene Diisocyanate
  • f) Commercial name: Desmodur® N 3200
  • 12) Amine-Functional Resin
  • a) Source: Bayer Corp, Pittsburgh, Pa.
  • b) Chemical family: amine-functional reactive partner for polyisocyanates.
  • c) Description/use: Crosslink with aliphatic polyisocyanate for polymer chain extension
  • d) Formula: [trade secret]
  • d) Commercial name: Desmophen® NH 1420
  • 13) Modified Polyether Polyol
  • a) Source: Bayer Corp, Pittsburgh, Pa.
  • b) Chemical family: CAS. No. 25723-16-4—Propylene oxide adduct of trimethylol propane
  • c) Description/use: MDI-activated thermoset—polymer converter
  • d) Formula: 1,2,3-tris (hydroxymethyl) propane.
  • 14) Ethyl Glycol. Polyol component of stabilizing carrier
  • a) Available from numerous chemical distributors
  • b) Chemical family: CAS #107-21-1
  • c) Description/use: Solvent carrier/reactant
  • d) Chemical Name: 1,2-dihydroxyethane, 1,2-ethanediol, ethane-1,2-diol
  • 15) Propylene Glycol. Polyol component of stabilizing carrier
  • a) Available from numerous chemical distributors
  • b) Chemical family: CAS #57-55-6
  • c) Description/use: Solvent carrier/reactant
  • d) Chemical name: 1,2-propanediol; 1,2-dihdroxypropane; methyl glycol; methylethylene glycol
  • e) Formula: C3H8O2
  • 16) Acetone, aka Propanone—Solvent Carrier/Reactant
  • a) Available from numerous chemical distributors
  • b) Chemical family: CAS. #67-64-1 Propanone, Acetone,
  • c) Description/use: Solvent carrier/reactant
  • 17) Acetate, aka Ethanoate, —Solvent Carrier/Reactant
  • a) Available from numerous chemical distributors
  • b) Chemical family: Anion of a salt or ester of acetic acid
  • c) Description/use: Solvent carrier/reactant
  • d) Formula: CH3CO2
  • 18) Mineral Spirits. Solvent Carrier/Reactant
  • a) Available from numerous chemical distributors
  • b) Chemical family: CAS #8052-41-3
  • c) Description/use: Solvent carrier/reactant
  • d) Formula: Stoddard Standard
  • 19) Methyl Ethyl Ketone. Solvent Carrier/Reactant
  • a) Available from numerous chemical distributors
  • b) Chemical family: CAS #78-93-3
  • c) Description/use: Solvent carrier/reactant
  • d) Chemical name: Ethyl Methyl Ketone
  • e) Formula: C4H8O
  • Formulations and Experimental Results
  • The following representative formulations of the treatment devices of the present invention are provided. All component amounts are identified in terms of stoichiometrically balanced volume amounts expressed as milliliters.
  • Liquid thermosetting, hydrophobic, elastomeric, non-toxic polymer solution treatment devices were prepared by adding the reactants in the sequence given. The stoichiornetrically determined volume amounts are expressed in milliliters. Solutions were stir-blended constantly at 20 paddle revolutions per minute during the sequential addition of the ingredients, and for 15-20 minutes after addition of the last ingredient. These parameters of the stir-blending process, in terms of revolutions and time, are the most optimum for obtaining maximum sequential reactivity of the ingredients during blending. The sequential mixing process was done at ambient conditions of 70-80° Fahrenheit, about 750-760 mm Hg, and relative humidity of 50-65%.
  • The treatment devices were applied according to the following recommended regimens. For nail fungus:
    • 1) Cut affected nail(s) as even with tip of toe(s) or finger(s) as possible.
    • 2) File or sand nail(s) down to at least 10-15 mils thickness (But closer to normal nail thickness should yield better effectiveness) Discard file after use and replace to avoid cross contamination of other nails and re-exposure after treatment.
    • 3) Use nail pick or scraper to remove any dead and/or infected loose tissue from underneath the tip of the nail(s). Discard and replace after use.
    • 4) Wash nail(s) and surrounding area with anti-bacteria soap and water, then dry thoroughly.
    • 5) Using a Q-tip applicator, swab nail and surrounding area, with 70% Isopropyl alcohol or nail polish remover to remove excess moisture, oils, and debris that could inhibit penetration and bonding. DO NOT place applicator back into solution after contact with infected nail(s). Discard and replace applicator.
    • 6) Apply a light topical coating of the treatment device over the prepared nail(s), the surrounding nail cuticle(s) and underneath the nail tip(s).
    • 7) Allow to cure to a tack-free state exposed to room air. Dry-time may be accelerated by using a blow dryer on cool setting, ten minutes after application.
    • 8) Apply next topical treatment in 24 hours, following Steps #4 thorough #7.
    • 9) Following treatments are at 72-hour intervals.
    • 10) Record application details, results, and condition status.
  • For poison ivy infections, the following regimen was observed:
    • 1) Wash affected are with anti-bacterial soap and water, then dry.
    • 2) Apply a light topical coating of treatment device and allow to cure to tack-free state at ambient temperature. Record any noticeable immediate reactions or changes in condition.
  • These treatment regimens were observed for the following formulations, with the results indicated.
    Treatment Device Formulation #1 Working Identifier:
    PMS-1 P-1000
    Stoichiometric
    Volume Volume
    Reagent [ml] Ratio
    Acetone 240 0.505
    Acetate 126.75 0.267
    Versalink ® P-1000 55.5 0.117
    Ethyl Glycol 7.5 0.016
    Propylene Glycol 7.5 0.016
    Rubinate ® 9259 or 2143 37.5 0.079
    Total: 474.75 1.000
  • Treatment 1: Poison Ivy infection covering 6 sq. in. of left arm of adult male. Itching stopped in less than a second. Condition cleared in two days. No side effects.
  • Treatment 2: Poison Ivy infection covering 4 sq. in. on right heel of adult male. Itching stopped in less than a second. Cool to the touch; no burning.
  • Treatment 3: Six-month nail fungus infection of adult male. Cleared up and has not recurred.
    Treatment Device Formulation #2 Working Identifier: PMS-3
    Stoichiometric
    Volume Volume
    Reagent [ml] Ratio
    Acetone 2888 0.752
    Acetate 228 0.059
    Jeffamine ® D-2000 304 0.080
    Unilink ® 4200 76 0.020
    4012 144 0.038
    No. 218 Isocyanate 198 0.051
    Total: 3838 1.000
  • Treatment 1: Poison Ivy infection covering 6 sq. in. of right back of adult male. Itching stopped in less than a second. Condition cleared in two days. No sting. Cool to the touch.
  • Treatment 2: Twenty-five year chronic nail fungus infection in both big toes and right thumb of adult male. Thumb cleared and significant progress in both toes over 10-week treatment regimen.
    Treatment Device Formulation #3 Working Identifier: PMS-1 White
    Stoichiometric
    Volume Volume
    Reagent [ml] Ratio
    Acetone 132 0.697
    Mineral Spirits 44 0.232
    4012 2.2 0.012
    Jeffamine ® D-2000 8.8 0.046
    No. 218 Isocyanate 2.4 0.013
    Total: 189.4 1.000
  • Treatment 1: One-year chronic nail fungus infection of left big toe of adult male. Condition 60% cleared in sixteen days, when subject ran out of treatment device. Treatment regiment resumed upon re-supply, and condition 100% cleared in two months.
  • Additional formulations of the medical device of the present invention are presented below.
    Formulations of Working Identifier: PMS-1
    Volume Volume Volume Volume Volume Volume
    Reagent [ml] Ratio [ml] Ratio [ml] Ratio
    Acetone 106.8 0.702 132.0 0.697 132.0 0.705
    Mineral Spirits 35.6 0.234 44.0 0.232 44.0 0.235
    Jeffamine ® 6.6 0.043 8.8 0.046 8.8 0.047
    D-2000
    Unilink ® 1.2 0.008
    4200
    4012 2.2 0.012
    No. 218 2.0 0.013 2.4 0.013 2.4 0.013
    Isocyanate or
    Lupranate ®
    81 Isocyanate
    Total 152.2 1.000 189.4 1.000 137.2 1.000
  • Formulations of Working Identifier: PMS-3
    Volume Volume Volume Volume
    Reagent [ml] Ratio [ml] Ratio
    Acetone 650.0 0.776 850.0 0.782
    MEK 50.0 0.059 100.0 0.092
    Jeffamine ® D-2000 60.0 0.071 60.0 0.055
    Unilink ® 4200 15.0 0.020 15.0 0.014
    4012 20.0 0.024 20.0 0.018
    Ethyl Glycol 5.0 0.006 5.0 0.005
    Propylene Glycol 5.0 0.006 5.0 0.005
    Lupranate ® 81 Isocyanate 32.0 0.038 32.0 0.029
    Total 837 1.000 1087 1.000
  • The medical device formulations of the present invention have the following physiological properties.
  • 1. Non-Cytotoxic, MEM Elusion—MG 023-0 Dilution
  • 2. Non-Hemolytic—In Vitro
  • 3. Non-Pyrogenic—Test T 10, Material Mediated
  • 4. Non-Carcinogenic—Standard Ames Salmonena Tests
  • Although the present invention has been described herein with respect to particular features, aspects and embodiments thereof, it will be apparent that numerous variations, modifications, and other embodiments are possible within the broad scope of the present invention, and accordingly, all variations, modifications and embodiments are to be regarded as being within the scope of the invention. The present embodiments are therefore to be construed in all aspects as illustrative and not restrictive and all changes coming within the meaning and equivalency range of the appended claims are intended to be embraced therein.

Claims (29)

  1. 1. A composition for the topical treatment of onychomycosis and urushiol-induced allergic contact dermatitis, the composition comprising a mixture of:
    a primary diamine in a volume ratio ranging from about 3.6% to about 12.2% v/v of the total solution;
    a chain extension reagent in a volume ratio ranging from about 2.0% to about 6.2% v/v of the composition; and
    a stabilizing carrier in an amount sufficient to prevent formation of a gel or solid prior to removal of a portion of the stabilizing carrier.
  2. 2. The composition of claim 1 wherein the volume ratio of the primary diamine ranges from about 5.8% to about 9.6% v/v of the total solution.
  3. 3. The composition of claim 1 wherein the volume ratio of the primary diamine ranges from about 6.2% to about 7.8% v/v of the total solution.
  4. 4. The composition of claim 1 further comprising a secondary diamine in a volume ratio ranging from about 0.6% to about 6.8% v/v of the total solution.
  5. 5. The composition of claim 1 wherein the volume ratio of the secondary diamine ranges from about 2.4% to about 4.8% v/v of the total solution.
  6. 6. The composition of claim 1 wherein the volume ratio of the secondary diamine ranges from about 2.8% to about 3.8% v/v of the total solution.
  7. 7. The composition of claim 4 wherein the primary diamine and the secondary diamine are stoichiometrically balanced.
  8. 8. The composition of claim 1 wherein the primary diamine is a polyoxypropylene diamine.
  9. 9. The composition of claim 4 wherein the secondary diamine is a dialkylamino diphenylamines.
  10. 10. The composition of claim 4 wherein the ratio of the primary diamine and secondary diamine to the chain extension reagent is from about 2.8:1 to about 3.8:1 by volume.
  11. 11. The composition of claim 1 wherein the chain extension reagent is selected from the group consisting of methylene-4,4′-diphenyl diisocyanate [MDI], MDI-containing resins, modified MDI, MDI-containing resins, aliphatic diisocyanates, aromatic diisocyanates, alicyclic diisocyanates, ethylene diisocyanate, ethylidene diisocyanate, propylene diisocyanate, butylene diisocyanate, cyclopentylene-1,3-diisocyanate, cyclohexylene-l,4-diisocyanate, cyclohexylene-1,2.diisocyanate, 2,4-tolylene diisocyanate, 2,6-tolylene diisocyanate, 4,4′-diphenylmethane diisocyanate, 2,2-diphenylpropane-4,4′-diisocyanate, p-phenylene diisocyanate, m-phenylene 15 diisocyanate, xylylene diisocyanate, 1,4-napthylene diisocyanate, 1,5-naphthylene diisocyanate, diphenyl-4,4′ diisocyanate, azobenzene-4,4′-diisocyanate, diphenylsulfone-4,4′-diisocyanate, dichlorohexamethylene diisocyanate, tetramethylene diisocyanate, pentametylene diisocyanate, hexamethylene diisocyanate, 1-chlorobenzene-2,4-diisocyanate, furfurylidene diisocyanate and triphenyl methane triisocyanate
  12. 12. The composition of claim 1 wherein the chain stabilizing carrier is provided in an amount from about 60% to about 80% v/v of the composition.
  13. 13. The composition of claim 1 wherein the stabilizing carrier is selected from the group consisting of: acetone, methyl ethyl ketone, methylisobutylketone, N-methylcyclohexanone, acetaldehyde, propionaldehyde, butryaldehyde, isobutyraldehyde, methyl acetate, ethyl acetate, butyl acetate, methoxy propyl acetate, ethylene glycol, propylene glycol, butylene glycols, polyethylene glycol 200, polyethylene glycol 400 and polyethylene glycol 600.
  14. 14. The composition of claim 1 further comprising a secondary carrier for regulating viscosity.
  15. 15. The composition of claim 14 wherein the secondary carrier is provided in an amount from about 20% to about 38% v/v of the composition.
  16. 16. The composition of claim 14 wherein the secondary carrier is selected from the group consisting of: mineral spirits, N-methyl pyrrolidone and Solvesso solvent Lactone.
  17. 17. The composition of claim 1 further comprising a poly(oxyalkalene)polyol in an amount sufficient to support the function of the carrier solvent reactant.
  18. 18. The composition of claim 17 wherein the poly(oxyalkalene)polyol is provided in an amount from about 3.2% to about 4.6% v/v of the composition.
  19. 19. The composition of claim 18 wherein the poly(oxyalkalene)polyol is selected from the group consisting of: propylene oxide adducts of trimethylol propane, (C3HO)12C6H14O3 and CAS #25723-16-4.
  20. 20. The composition of claim 1 further comprising a colorant or pigment.
  21. 21. A method of treating onychomycosis or urushiol-induced allergic contact dermatitis by topical application of a polyureathane linked copolymer, comprising:
    combining a primary diamine with modified diphenylmethane diisocyanates and a first carrier solvent/reactant to form a solution;
    coating an affected nail or skin with the solution; and
    drying the solution to form a polyureathane linked copolymer coating over the affected area.
  22. 22. The method of claim 21 further comprising combing the primary diamine with a secondary diamine in an oligomeric, stoichiometrically balanced blend.
  23. 23. The method of claim 21 wherein the first carrier solvent/reactant comprises acetone.
  24. 24. The method of claim 21 wherein the solution additionally includes a second carrier solvent/reactant.
  25. 25. The method of claim 24 wherein the second carrier solvent/reactant comprises mineral spirits.
  26. 26. The method of claim 21 wherein the solution additionally includes a polyether oxyalkylene polyol.
  27. 27. The method of claim 21 wherein polymerization of the polyureathane linked copolymer is initiated immediately upon application of the polyureathane linked copolymer to the skin or nail, without a modification of external ambient conditions.
  28. 28. The method of claim 21 wherein the polyureathane linked copolymer has a % distention-to-yield value of about 450% to about 680%.
  29. 29. The method of claim 21 wherein the solution further includes a colorant or stain.
US11284649 2002-08-20 2005-11-22 Hydrophobic elastomeric polymer chemistry device for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis Abandoned US20060216267A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US22399102 true 2002-08-20 2002-08-20
US10757294 US7008997B2 (en) 2002-08-20 2004-01-14 Non-toxic hydrophobic elastomeric polymer chemistry system for wood preservation
US11284649 US20060216267A1 (en) 2002-08-20 2005-11-22 Hydrophobic elastomeric polymer chemistry device for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11284649 US20060216267A1 (en) 2002-08-20 2005-11-22 Hydrophobic elastomeric polymer chemistry device for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis
PCT/US2006/061179 WO2007062381A3 (en) 2005-11-22 2006-11-22 Hydrophobic elastomeric polymer chemistry device for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis
CN 200680050974 CN101378765B (en) 2005-11-22 2006-11-22 Hydrophobic elastomeric polymer chemical method for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis
EP20060839991 EP1962866B1 (en) 2005-11-22 2006-11-22 Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same
CA 2633549 CA2633549C (en) 2005-11-22 2006-11-22 Hydrophobic elastomeric polymer chemistry device for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis
US12103353 US9402860B2 (en) 2002-08-20 2008-04-15 Methods of inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10757294 Continuation-In-Part US7008997B2 (en) 2002-08-20 2004-01-14 Non-toxic hydrophobic elastomeric polymer chemistry system for wood preservation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12103353 Division US9402860B2 (en) 2002-08-20 2008-04-15 Methods of inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis

Publications (1)

Publication Number Publication Date
US20060216267A1 true true US20060216267A1 (en) 2006-09-28

Family

ID=38068043

Family Applications (2)

Application Number Title Priority Date Filing Date
US11284649 Abandoned US20060216267A1 (en) 2002-08-20 2005-11-22 Hydrophobic elastomeric polymer chemistry device for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis
US12103353 Active 2025-11-01 US9402860B2 (en) 2002-08-20 2008-04-15 Methods of inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12103353 Active 2025-11-01 US9402860B2 (en) 2002-08-20 2008-04-15 Methods of inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis

Country Status (5)

Country Link
US (2) US20060216267A1 (en)
EP (1) EP1962866B1 (en)
CN (1) CN101378765B (en)
CA (1) CA2633549C (en)
WO (1) WO2007062381A3 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203040A1 (en) * 2006-02-24 2007-08-30 Harry Reicherz Bar soap
US20080253984A1 (en) * 2002-08-20 2008-10-16 Kovacs Stephen G Methods of inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis
US20090098194A1 (en) * 2007-10-12 2009-04-16 Jerry Chesson Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same
US20090220397A1 (en) * 2008-01-28 2009-09-03 Battelle Memorial Institute Capture and Release of Acid-Gasses with Acid-Gas Binding Organic Compounds
US20100286754A1 (en) * 2009-05-06 2010-11-11 Bly Deborah C Assembly and method for treating and preventing moisture related skin dermatitis

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107457857A (en) * 2017-09-11 2017-12-12 阜南县大自然工艺品有限公司 Method for preventing cracking of sheet wood artware

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438374A (en) * 1966-02-28 1969-04-15 Us Health Education & Welfare Method of bonding tissue surfaces and controlling hemorrhaging thereof using a tissue adhesive and hemostatic composition
US4474900A (en) * 1983-06-08 1984-10-02 Texaco Inc. Reaction injection molded elastomers
US4560555A (en) * 1982-12-17 1985-12-24 Sogimi S.R.L. Reactive polymers for dermal and transdermal therapy
US4581432A (en) * 1983-11-29 1986-04-08 Basf Aktiengesellschaft Heat-curable compositions which are storage-stable at room temperature and are based on compounds having reactive hydrogen atoms and polyisocyanates
US4653493A (en) * 1985-02-08 1987-03-31 Hoppough John M Ventilator unit exhalation contamination control device
US4720535A (en) * 1986-03-11 1988-01-19 Basf Aktiengesellschaft Moisture tempered, storage stable single component polyurethane systems and their application
US4806615A (en) * 1987-06-01 1989-02-21 Texaco Inc. Reaction injection molded elastomers prepared from amine terminated polyethers, a blend of an aromatic amine terminated chain extender, a substituted acyclic aliphatic amine terminated chain extender and an aromatic polyisocyanate
US4913897A (en) * 1987-12-28 1990-04-03 Bio-Products, Inc. Use of hydrogel solutions to form a hydrophilic protective film on the skin against toxic substances, pollutants, infections and skin secretions
US4960620A (en) * 1988-06-17 1990-10-02 Uop Coating method for room-temperature-cured polyurethanes and polyureas
US5013813A (en) * 1989-12-18 1991-05-07 Texaco Chemical Company Polyurea elastomer with rapid dry time
US5160328A (en) * 1991-08-07 1992-11-03 Ndm Acquisition Corp. Hydrogel bandage
US5192536A (en) * 1990-10-26 1993-03-09 Huprich Carl A Method and composition for coating a wound with polyether polyurethane
US5346692A (en) * 1992-04-10 1994-09-13 Roehm Pharma Gmbh Nail lacquer for the treatment of onychomycosis
US5374704A (en) * 1992-12-23 1994-12-20 Bayer Aktiengesellschaft Pure, in particular catalyst-free polyurethanes
US5616677A (en) * 1994-06-24 1997-04-01 Huntsman Petrochemical Corporation Preparation of sprayable aliphatic polyurea elastomers having improved properties
US5738627A (en) * 1994-08-18 1998-04-14 Duke University Bi-ventricular cardiac assist device
US5763734A (en) * 1995-10-19 1998-06-09 Nachtman; Thomas J. Method for containing or removing contaminants from a substrate
US20010051135A1 (en) * 1998-08-27 2001-12-13 Jean-Michel Sturla Aerosol device containing a polycondensate comprising at least one polyurethane and/or polyurea unit
US6359100B1 (en) * 1998-01-28 2002-03-19 Bristol-Myers Squibb Company Methods of preparing polyurethane adhesives, adhesives produced thereby and medical devices employing the same
US6358503B1 (en) * 2000-09-26 2002-03-19 Coloplast Corp. Protectant film for skin
US6403063B1 (en) * 1999-07-26 2002-06-11 Kenneth I. Sawyer Method of treating nail fungus
US6495119B1 (en) * 1998-08-27 2002-12-17 L'oreal S.A. Aerosol device containing a polycondensate comprising at least one polyurethane and/or polyurea unit
US6552155B1 (en) * 1999-04-25 2003-04-22 Kenneth I. Sawyer Polyaldimines of oligomeric aminobenzoic acid derivatives, and their use for preparation of moisture-curable, storage-stable, one-part polyreas
US6627216B2 (en) * 1998-08-20 2003-09-30 3M Innovative Properties Company Spray on bandage and drug delivery system
US6784273B1 (en) * 1998-06-05 2004-08-31 Polyganics B.V. Biomedical polyurethane, its preparation and use
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US7078475B2 (en) * 2001-06-15 2006-07-18 Huntsman Petrochemical Corporation Synergistic amine chain-extenders in polyurea spray elastomers
US20070041935A1 (en) * 2005-08-17 2007-02-22 Salamone Ann B Conformable solvent-based bandage and coating material

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3194793A (en) * 1961-12-13 1965-07-13 Du Pont Polyurethanes cured with mixtures of aromatic primary and secondary diamines
US3892696A (en) 1972-05-12 1975-07-01 Grace W R & Co Polyureas and preparation thereof
US3893969A (en) * 1974-03-29 1975-07-08 Gen Motors Corp Reinforced polyamide molding composition
DE2921163A1 (en) 1979-05-25 1980-12-04 Bayer Ag Self-curing material for the manufacture of a witterungsbestaendigen, non-yellowing stuetzverbands
US4328322A (en) 1979-12-03 1982-05-04 Polaroid Corporation Synthetic polymers by polyisocyanate polyaddition process
US4542012A (en) 1982-07-02 1985-09-17 Minnesota Mining And Manufacturing Company Film-forming composition containing an antimicrobial agent and methods
US4584192A (en) 1984-06-04 1986-04-22 Minnesota Mining & Manufacturing Company Film-forming composition containing an antimicrobial agent and methods of use
EP0215072A4 (en) 1985-03-13 1990-01-08 Gluck Bruno A Antiseptic fluids.
US4733659A (en) 1986-01-17 1988-03-29 Seton Company Foam bandage
US4655210A (en) 1986-01-17 1987-04-07 Seton Company Foam bandage
JP2577900B2 (en) 1987-02-18 1997-02-05 イハラケミカル工業 株式会社 The method of producing polyurea resin
US5103812A (en) 1988-10-12 1992-04-14 Rochal Industries, Inc. Conformable bandage and coating material
DE3940273A1 (en) 1989-12-06 1991-06-13 Bayer Ag Heat-curable polyether-polyester-polyurethane ureas
US5104930A (en) 1990-02-27 1992-04-14 Raychem Corporation Polyurea gel compositions and articles therefrom
US5259835A (en) 1991-08-29 1993-11-09 Tri-Point Medical L.P. Wound closure means and method using flowable adhesive
US5319058A (en) 1991-10-22 1994-06-07 Ihara Chemical Industry Co., Ltd. Method for the preparation of a polyurea resin
DK5492D0 (en) 1992-01-17 1992-01-17 Coloplast As A dressing
JP4260878B2 (en) 1994-01-21 2009-04-30 スリーエム カンパニー Orthopedic casting tape and a method of manufacturing the same
US5981621A (en) 1996-02-29 1999-11-09 Closure Medical Corporation Monomeric compositions effective as wound closure devices
US20040137067A1 (en) 1998-04-30 2004-07-15 Closure Medical Corporation Adhesive applicator tip with a polymerization initiator, polymerization rate modifier, and/or bioactive material
US20030080151A1 (en) 1998-10-22 2003-05-01 Closure Medical Corporation Applicator with protective barrier
US20050033251A1 (en) 1998-12-08 2005-02-10 Quick-Med Technologies, Inc. Controlled release of biologically active substances from select substrates
WO2001013956A3 (en) * 1999-08-26 2001-10-04 Ganeden Biotech Inc Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
US6620846B1 (en) 2000-08-02 2003-09-16 Closure Medical Corporation Absorbable adhesive compositions
US7303759B2 (en) 2001-06-22 2007-12-04 The United States Of America As Represented By The Secretary Of The Army Compositions and methods for reducing blood and fluid loss from open wounds
US6942875B2 (en) 2001-07-05 2005-09-13 Closure Medical Corporation Adhesive treatment for skin yeast infections
US6602496B2 (en) 2001-07-05 2003-08-05 Closure Medical Corporation Adhesive treatment for tinea corporis
US6767552B2 (en) 2001-07-05 2004-07-27 Closure Medical Corporation Adhesive treatment for oral fungal infection
US6585967B2 (en) 2001-07-05 2003-07-01 Closure Medical Corporation Adhesive treatment for tinea cruris
US6746667B2 (en) 2001-07-05 2004-06-08 Closure Medical Corporation Adhesive treatment for tinea pedis
WO2003075968A3 (en) 2002-03-04 2003-12-18 Georgia Tech Res Inst Biocompatible hydrophilic films from polymeric mini-emulsions for application to skin
WO2004018171A1 (en) * 2002-08-20 2004-03-04 Roof Matrix, Inc. Non-toxic hydrophobic elastomeric polymer chemistry system for wood preservation
US20060216267A1 (en) 2002-08-20 2006-09-28 Kovacs Stephen G Hydrophobic elastomeric polymer chemistry device for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis
US7378479B2 (en) 2002-09-13 2008-05-27 Lubrizol Advanced Materials, Inc. Multi-purpose polymers, methods and compositions
US20040241130A1 (en) 2002-09-13 2004-12-02 Krishnan Tamareselvy Multi-purpose polymers, methods and compositions
US7135194B2 (en) * 2002-09-27 2006-11-14 Birnbaum Jay E Subunguicide, and method for treating onychomycosis
WO2004032713A3 (en) 2002-10-04 2004-08-12 Nanomatrix Inc Sealants for skin and other tissues
DE10316014A1 (en) 2003-04-07 2004-10-21 Dähne, Philipp Apparatus and method for improving flow flux of biological fluids by means of a self-propelled rotatable pipe spacer
WO2004093786A3 (en) 2003-04-16 2006-03-23 Corium Int Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith
US20040223932A1 (en) 2003-05-05 2004-11-11 Closure Medical Corporation Adhesive treatment for acne
WO2005049105A8 (en) 2003-11-10 2005-10-13 Angiotech Int Ag Medical implants and anti-scarring agents
US20050271794A1 (en) 2003-12-24 2005-12-08 Synecor, Llc Liquid perfluoropolymers and medical and cosmetic applications incorporating same
US20050273146A1 (en) 2003-12-24 2005-12-08 Synecor, Llc Liquid perfluoropolymers and medical applications incorporating same
KR100810947B1 (en) 2005-01-28 2008-03-10 롬 앤드 하아스 컴패니 Medical films and articles prepared from emulsion polymers
US7318937B2 (en) 2005-03-18 2008-01-15 Closure Medical Corporation Liquid coating compositions
WO2007025293A3 (en) 2005-08-26 2007-08-02 Univ North Carolina Use of acid derivatives of fluoropolymers for fouling-resistant surfaces
US20070048355A1 (en) 2005-08-26 2007-03-01 Daniel Perlman Non-irritating solvent-borne polymeric coatings for application to the skin
US8771725B2 (en) * 2007-10-12 2014-07-08 Chesson Laboratory Associates, Inc. Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438374A (en) * 1966-02-28 1969-04-15 Us Health Education & Welfare Method of bonding tissue surfaces and controlling hemorrhaging thereof using a tissue adhesive and hemostatic composition
US4560555A (en) * 1982-12-17 1985-12-24 Sogimi S.R.L. Reactive polymers for dermal and transdermal therapy
US4474900A (en) * 1983-06-08 1984-10-02 Texaco Inc. Reaction injection molded elastomers
US4581432A (en) * 1983-11-29 1986-04-08 Basf Aktiengesellschaft Heat-curable compositions which are storage-stable at room temperature and are based on compounds having reactive hydrogen atoms and polyisocyanates
US4653493A (en) * 1985-02-08 1987-03-31 Hoppough John M Ventilator unit exhalation contamination control device
US4720535A (en) * 1986-03-11 1988-01-19 Basf Aktiengesellschaft Moisture tempered, storage stable single component polyurethane systems and their application
US4806615A (en) * 1987-06-01 1989-02-21 Texaco Inc. Reaction injection molded elastomers prepared from amine terminated polyethers, a blend of an aromatic amine terminated chain extender, a substituted acyclic aliphatic amine terminated chain extender and an aromatic polyisocyanate
US4913897A (en) * 1987-12-28 1990-04-03 Bio-Products, Inc. Use of hydrogel solutions to form a hydrophilic protective film on the skin against toxic substances, pollutants, infections and skin secretions
US4960620A (en) * 1988-06-17 1990-10-02 Uop Coating method for room-temperature-cured polyurethanes and polyureas
US5013813A (en) * 1989-12-18 1991-05-07 Texaco Chemical Company Polyurea elastomer with rapid dry time
US5192536A (en) * 1990-10-26 1993-03-09 Huprich Carl A Method and composition for coating a wound with polyether polyurethane
US5160328A (en) * 1991-08-07 1992-11-03 Ndm Acquisition Corp. Hydrogel bandage
US5346692A (en) * 1992-04-10 1994-09-13 Roehm Pharma Gmbh Nail lacquer for the treatment of onychomycosis
US5374704A (en) * 1992-12-23 1994-12-20 Bayer Aktiengesellschaft Pure, in particular catalyst-free polyurethanes
US5616677A (en) * 1994-06-24 1997-04-01 Huntsman Petrochemical Corporation Preparation of sprayable aliphatic polyurea elastomers having improved properties
US5908378A (en) * 1994-08-18 1999-06-01 Duke University Bi-ventricular cardiac assist device
US5738627A (en) * 1994-08-18 1998-04-14 Duke University Bi-ventricular cardiac assist device
US5763734A (en) * 1995-10-19 1998-06-09 Nachtman; Thomas J. Method for containing or removing contaminants from a substrate
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US6359100B1 (en) * 1998-01-28 2002-03-19 Bristol-Myers Squibb Company Methods of preparing polyurethane adhesives, adhesives produced thereby and medical devices employing the same
US6784273B1 (en) * 1998-06-05 2004-08-31 Polyganics B.V. Biomedical polyurethane, its preparation and use
US6627216B2 (en) * 1998-08-20 2003-09-30 3M Innovative Properties Company Spray on bandage and drug delivery system
US6958154B2 (en) * 1998-08-20 2005-10-25 3M Innovative Properties Company Spray on bandage and drug delivery system
US6495119B1 (en) * 1998-08-27 2002-12-17 L'oreal S.A. Aerosol device containing a polycondensate comprising at least one polyurethane and/or polyurea unit
US20010051135A1 (en) * 1998-08-27 2001-12-13 Jean-Michel Sturla Aerosol device containing a polycondensate comprising at least one polyurethane and/or polyurea unit
US6552155B1 (en) * 1999-04-25 2003-04-22 Kenneth I. Sawyer Polyaldimines of oligomeric aminobenzoic acid derivatives, and their use for preparation of moisture-curable, storage-stable, one-part polyreas
US6403063B1 (en) * 1999-07-26 2002-06-11 Kenneth I. Sawyer Method of treating nail fungus
US6358503B1 (en) * 2000-09-26 2002-03-19 Coloplast Corp. Protectant film for skin
US7078475B2 (en) * 2001-06-15 2006-07-18 Huntsman Petrochemical Corporation Synergistic amine chain-extenders in polyurea spray elastomers
US20070041935A1 (en) * 2005-08-17 2007-02-22 Salamone Ann B Conformable solvent-based bandage and coating material

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080253984A1 (en) * 2002-08-20 2008-10-16 Kovacs Stephen G Methods of inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis
US9402860B2 (en) 2002-08-20 2016-08-02 Chesson Laboratory Associates, Inc. Methods of inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis
US20070203040A1 (en) * 2006-02-24 2007-08-30 Harry Reicherz Bar soap
US20090098194A1 (en) * 2007-10-12 2009-04-16 Jerry Chesson Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same
US9259436B2 (en) * 2007-10-12 2016-02-16 Chesson Laboratory Associates, Inc. Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same
US8771725B2 (en) * 2007-10-12 2014-07-08 Chesson Laboratory Associates, Inc. Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same
US20140212370A1 (en) * 2007-10-12 2014-07-31 Chesson Laboratory Associates, Inc. Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same
US8980210B2 (en) * 2008-01-28 2015-03-17 Battelle Memorial Institute Capture and release of acid-gasses with acid-gas binding organic compounds
US20090220397A1 (en) * 2008-01-28 2009-09-03 Battelle Memorial Institute Capture and Release of Acid-Gasses with Acid-Gas Binding Organic Compounds
US8480724B2 (en) 2009-05-06 2013-07-09 Deborah C Bly Assembly and method for treating and preventing moisture related skin dermatitis
US20100286754A1 (en) * 2009-05-06 2010-11-11 Bly Deborah C Assembly and method for treating and preventing moisture related skin dermatitis
US9775740B2 (en) 2009-05-06 2017-10-03 Deborah C Bly Assembly for treating and preventing moisture related skin dermatitis

Also Published As

Publication number Publication date Type
CA2633549C (en) 2014-06-03 grant
CA2633549A1 (en) 2007-05-31 application
EP1962866A4 (en) 2012-11-14 application
EP1962866A2 (en) 2008-09-03 application
US9402860B2 (en) 2016-08-02 grant
CN101378765A (en) 2009-03-04 application
CN101378765B (en) 2013-07-17 grant
WO2007062381A3 (en) 2007-11-08 application
EP1962866B1 (en) 2015-03-18 grant
WO2007062381A2 (en) 2007-05-31 application
US20080253984A1 (en) 2008-10-16 application

Similar Documents

Publication Publication Date Title
US3567692A (en) Polymeric materials produced by interacting polyisocyanate and water in the presence of polyaldimine or polyketimine
Artschwager Wound periderm formation in the potato as affected by temperature and humidity
US4996054A (en) Antithrombogenic, non-calcifying material and method of making articles for medical purposes
US6143794A (en) Topical formulations for the treatment of nail fungal diseases
US5000955A (en) Thermally reversible polyurethane hydrogels and cosmetic, biological and medical uses
US3917850A (en) Biocidal synergistic compositions for surface and space disinfection
D'arcy et al. The anti‐inflammatory action of griseofulvin in experimental animals
US6372876B1 (en) Use of polyurethanes which are soluble or dispersible in water as aids in cosmetic and pharmaceutical compositions, and polyurethanes which contain polylactic acid polyols as copolymerized units
US5906808A (en) Process of preparing a topical antimicrobial cleanser
US3805531A (en) Consolidation of mineral aggregate
US5017382A (en) Controlled release compositions (II)
USRE32476E (en) Consolidation of aggregate material
Stannard Separation of the resting and activity oxygen consumptions of frog muscle by means of sodium azide
US20040202707A1 (en) Therapeutic patch
US20090076109A1 (en) Pharmaceutical Composition for External Use
US5910312A (en) Acne treatment composition with vasoconstrictor
US5227414A (en) Aqueous urethane-epoxy coating composition
Hui et al. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate
US3920436A (en) Artificial protective environment for plants
US20090137651A1 (en) Pharmaceutical composition for external use
US4127124A (en) Urethane bioimplant membrane
US3931111A (en) Soluble hydrophilic polymers and process for processing the same
US3281396A (en) Production of sprayed polyurethane film
US4997655A (en) Pharmaceutical formulation ensuring the transdermal absorption of the active ingredient and process for preparing same
Marty Amorolfine nail lacquer: a novel formulation

Legal Events

Date Code Title Description
AS Assignment

Owner name: ROOF MATRIX, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHESSON, JERRY S.;REEL/FRAME:017953/0988

Effective date: 20060530